VENTYX BIOSCIENCES IN

Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors

12 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Host R&D Event on January 26, 2023

05 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis

01 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

22 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

03 Nov 2022 15:01:01 By Nasdaq GlobeNewswire

Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022

27 Oct 2022 15:05:01 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

27 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock

19 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

29 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

15 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958

15 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022

11 Aug 2022 15:05:03 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735

29 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Jefferies Healthcare Conference

01 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

12 May 2022 15:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer

09 May 2022 07:00:01 By Nasdaq GlobeNewswire

Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022

05 May 2022 15:05:01 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress

23 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference

07 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis

06 Dec 2021 07:00:01 By Nasdaq GlobeNewswire